Study Objectives: Recent findings showed that 16%-26% of narcolepsy patients were positive for anti-tribbles pseudokinase 2 (TRIB2) antibody, and the intracerebroventricular administration of immunoglobulin-G purified from anti-TRIB2 positive narcolepsy patients caused hypocretin/orexin neuron loss. We investigated the pathophysiological role of TRIB2 antibody using TRIB2-immunized rats and hypocretin/ataxin-3 transgenic (ataxin-3) mice. Methods: Plasma, cerebrospinal fluid (CSF), and hypothalamic tissues from TRIB2-immunized rats were collected. Anti-TRIB2 titers, hypocretin contents, mRNA expressions, the cell count of hypocretin neurons, and immunoreactivity of anti-TRIB2 antibodies on hypocretin neurons were investigated. The plasma from ataxin-3 mice was also used to determine the anti-TRIB2 antibody titer changes following the loss of hypocretin neurons. Results: TRIB2 antibody titers increased in the plasma and CSF of TRIB2-immunized rats. The hypothalamic tissue immunostained with the sera from TRIB2-immunized rats revealed positive signals in the cytoplasm of hypcretin neurons. While no changes were found regarding hypothalamic hypocretin contents or cell counts, but there were significant decreases of the hypocretin mRNA level and release into the CSF. The plasma from over 26-week-old ataxin-3 mice, at the advanced stage of hypocretin cell destruction, showed positive reactions against TRIB2 antigen, and positive plasma also reacted with murine hypothalamic hypocretin neurons. Conclusions: Our results suggest that the general activation of the immune system modulates the functions of hypocretin neurons. The absence of a change in hypocretin cell populations suggested that factors other than anti-TRIB2 antibody play a part in the loss of hypocretin neurons in narcolepsy. The increased anti-TRIB2 antibody after the destruction of hypocretin neurons suggest that anti-TRIB2 antibody in narcolepsy patients is the consequence rather than the inciting cause of hypocretin cell destruction.
INTRODUCTION
Narcolepsy, a chronic sleep disorder, causes excessive daytime sleepiness and cataplexy as the primary symptoms. 1 The loss of hypothalamic hypocretin (also called orexin) neurons in the hypothalamus is thought to precede narcolepsy onset. 2 The allele of the Human Leukocyte Antigen (HLA) genotype (DQB1*0602 as susceptibility 3, 4 or DQB1*0603 as protective 5 ), polymorphisms in the T-cell receptor α locus, 6 and common variants in the purinergic receptor subtype P2Y11 7 are strongly associated with narcolepsy. The intravenous administration of immunoglobulin-G (IgG) was reported to improve cataplexy and normalize cerebrospinal fluid (CSF) hypocretin-1 in one case at the onset of narcolepsy. 8, 9 It has been hypothesized that an autoimmune-mediated process targeting hypothalamic hypocretin neurons contributes to narcolepsy. An ImmunoChip study provided supporting evidence for this autoimmune hypothesis of narcolepsy. 10 Cvetkovic-Lopes et al. reported that 16% of Caucasian narcolepsy patients have autoantibodies against tribbles pseudokinase 2 (TRIB2), which is highly expressed in hypothalamic hypocretin neurons. 11 We have also reported the presence of autoantibodies against TRIB2 in 25%-26% of Japanese and Caucasian narcolepsy patients. 12 , 13 These results suggest that a subgroup of narcolepsy is associated with a TRIB2 autoantibody-mediated autoimmune process.
However, it remains to be clarified whether a high titer of TRIB2 autoantibody is the cause of narcolepsy. There are three fundamental possibilities regarding the elevated titer of TRIB2 autoantibody: (1) serum TRIB2 autoantibody passes through the blood brain barrier to cause the degeneration of hypocretin neurons, (2) the TRIB2 autoantibody titer increases in the serum as a result of the loss of hypocretin neurons, and (3) an increase of the peripheral TRIB2 autoantibody titer and the loss of hypocretin neurons in the brain occurred simultaneously but independently by potentially common factors. 14 Although a recent finding showed that the intracerebroventricularly passive transfer of IgG purified from narcolepsy patients' sera positive for anti-TRIB2 autoantibody caused hypothalamic hypocretin neuron loss and sleep attacks in mice, 15 there still remains the possibility that serum factors other than anti-TRIB2 autoantibody were critical for these phenotypes. If peripheral TRIB2 autoantibodies have a causal relationship with narcolepsy-cataplexy, TRIB2 autoantibodies induced by immunization with TRIB2-peptide might lead to narcolepsy with cataplexy in an animal model. Moreover, if TRIB2 autoantibodies increase in the serum as a result of the loss of hypocretin neurons, they could be identified in hypocretin/ataxin-3 mice, whose hypocretin neurons are postnatally ablated. 16 In this study, we explored the pathophysiological role of TRIB2 autoantibodies against narcolepsy and hypocretin neurons using experimentally immunized rats with the C-terminal of the TRIB2 peptide and hypocretin/ataxin-3 mice to clarify
Statement of Significance
We investigated the pathophysiological role of TRIB2 antibody using TRIB2-immunized rats and hypocretin-ablated mice, and concluded that anti-TRIB2 antibody in narcolepsy patients is the consequence rather than the inciting cause of hypocretin cell destruction. Although general immune activation has been shown to be closely related to the function of hypocretin, the TRIB2 autoimmune mechanism was not found to be directly related to pathogenesis of narcolepsy. It is suggested that further investigation, such as demonstrating co-localization with cytokine receptors or major histocompatibility complex class I proteins in hypothalamic hypocretin neurons, is required in order to explore the complex immune factors on narcolepsy onset.
whether or not causal relationship exists between TRIB2 and narcolepsy.
MATERIALS AND METHODS

Animal Preparation
Thirty-two 5-week-old female Sprague Dawley (SD) rats, weighing 250-350 g, were housed in sound-attenuated light-controlled cages (LD 12:12, lights on at 7:00 am; off at 7:00 pm; a constant environment at 25 ± 1°C and 50 ± 10% relative humidity) for 2 weeks before immunization. Food and water were available ad libitum. Rats were given one of the following three subcutaneous injections; 30 micrograms (μG) keyhole limpet hemocyanin (KLH, n = 9), 30 μG C-terminal TRIB2 peptide (CDQLVPDVNMEENLDPFFN) conjugated to KLH (TRIB2, n = 16), or saline (intact, n = 10) every other week from 7 weeks old. We used 19 C-terminal amino acids of TRIB2 for immunization because our previous results suggested that anti-TRIB2 autoantibodies might recognize the TRIB2 C-terminal region, which has a low sequence homology with TRIB3. 12 CvetkovicLopes et al. 11 also used the C-teminal of the TRIB2 peptide for their work. Final immunization was conducted at the age of 19 weeks. CSF was obtained from 15-, 17-, 19-, and 21-week-old rats. Serum and brain samples were obtained from 21-week-old rats. Two weeks after the final immunization, exsanguination was conducted of all rats to obtain their sera. At the age of 21 weeks, three out of the 9 KLH-immunized rats were subjected to 6 hours of sleep deprivation.
Forty-two hypocretin/ataxin-3 (37 females and five males) mice were also housed in sound-attenuated light-controlled cages. Food and water were available ad libitum. The presence of the ataxin-3-transgene was identified by PCR using tail DNA. The plasma from 3-and 4-week-old mice (seven females and five males), 12-to 29-week-old mice (12 females), and 28-to 38-week-old mice (18 females) were obtained to determine the titers of anti-TRIB2 autoantibody.
All experiments were conducted in accordance with the "Guidelines for Care and Use of Laboratory Animals" of the National Institutes of Health and were approved by the ethics committee on animal experiments of Tokyo Metropolitan Institute of Medical Science.
Anti-TRIB2 ELISA
The anti-TRIB2 titers were measured by standard ELISA procedures using TRIB2 recombinant protein with a 26-kilodalton (kDa) N-terminal Gluthatione S-transferase tag purchased from Novus Biologicals (Littleton, CO). One hundred nanograms (nG) of TRIB2 antigens was deposited in 96-well ELISA plates and incubated overnight at 4°C. Wells were washed and blocked for 1 hour at room temperature with 5% BSA. One hundred microliters (μL) of diluted rat serum (1:100), CSF (1:100), or murine plasma (1: 100) was applied to the ELISA plate in triplicate for 1 hour at room temperature. ProteinG-Horseradish peroxidase (HRP) (diluted 1: 10 000) was then added and incubated for 1 hour at room temperature. Colorimetric assays were performed using TMB No Hydrogen Peroxide One Component Substrate (Promega KK, Tokyo, Japan). OD 595 was calculated for each well by Multiscan JX apparatus (ThermoFisher Scientific, Tokyo, Japan). The cut-off value was set at the mean + 3 SD in 10 intact rat sera (OD 595 = 1.860), in six intact rat CSF samples (OD 595 = 0.510), or in 3-and 4-week-old hypocretin/ ataxin-3 mice (12 females) (OD 595 = 0.207), respectively.
Hypocretin Measurement
Hypocretin-1 concentrations in rat hypothalamic extracts and CSF (50 μL) were measured by ELISA (Phoenix Pharmaceuticals Inc., Burlingame, CA). Brains were rapidly removed and the hypothalamus was dissected from the brain slice between interaural coordinates of 4.5-7.5 mm. Then, the tissues were boiled and homogenized in 1 M CH 3 COOH·20 mM HCl and then centrifuged at 20 000g for 15 minutes at 4°C. The supernatant was filtered (0.45 micrometer [μm]) and stored at −80°C until assay. All samples were measured in duplicate and the intra-assay variability was 5%-10% and inter-assay variability was less than 15%.
RNA Preparation and RT-Quantitative PCR
Hypothalami from 21-week-old rats were dissected coronally from the optic chiasma to mammillary bodies (−6 mm from the chiasma) using a brain slicer. The dorsal limit of the hypothalamus was the roof of the third ventricle, and the lateral limit was the amygdala. 17 Total RNA was isolated from the hypothalamus of individual rats using TRIZOL reagent (Invitrogen, Carlsbad, CA). Single-stranded cDNA was synthesized using the PrimeScript RT reagent kit with gDNA Eraser (Takara, Shiga, Japan). The relative expression levels of hypocretin and pro-melanin-concentrating hormone mRNA were determined with the ABI 7300 Reverse Transcriptase (RT)-Quantitative Polymerase Chain Reaction (PCR) system using SYBR Green Realtime PCR Master Mix -Plus-(Toyobo, Osaka, Japan) and the following gene-specific primers for rats: Hcrt_84F: 5′-AGACACCATGAACCTTCCTTCTAC-3′;
Hcrt_292R: 5′-GCTTTCCCAGAGTGAGGATG-3′; Pmch_460F: 5′-AAGAAAACTCAGCTAAATTTCCCATA-3′; Pmch_635R: 5′-AGTTACATCAACATTAAGGGCTTTTC-3′. We used B2m, Gapdh, and Tbp primer pairs from the Rat Housekeeping Gene Primer Set (Takara, Shiga, Japan) as housekeeping genes.
Immunohistochemistry
Brains from 21-week-old rats were removed quickly, fixed in 4% paraformaldehyde for 24 hours, and then allowed to equilibrate in 10%, 20%, and 30% sucrose in 0.1 M of PB with 0.01% sodium azide at 4°C. Serial coronal 25-μm-thick sections of the brain were made on a sliding freezing microtome, and stored in the refrigerator until use for immunohistochemistry. The brain sections were soaked in 0.3% Triton X and 0.01% H 2 O 2 in PBS for 2 hours at room temperature, and treated overnight with a blocking buffer consisting of 0.3% Triton X-PBS with 10% BlockAce (Dainihon-seiyaku, Osaka, Japan) and 2% normal goat serum (Vector Laboratories, Burlingame, CA). The sections were incubated further with rabbit anti-hypocretin-1 primary antiserum (1:4500, Phoenix Pharmaceuticals Inc.) diluted in 0.4% Triton X-PBS for 48 hours, and followed by 2 hours with goat anti-rabbit secondary antiserum (1:2000, Vector Laboratories). Hypocretin-immunoreactive neurons were visualized using a DAB reaction not containing NiCl 2 . After several washes in PBS, the sections were mounted onto gelatin-coated glass slides, dehydrated in alcohol, cleaned in xylene, and cover-slipped with mounting media (Entellan, Merck, Darmstadt, Germany).
The antibody used to identify hypocretin-immunoreactive neurons exhibits a 100% cross-reactivity with human, bovine, mouse, and rat hypocretin-1 but no cross reactivity with human hypocretin-2 or other related peptides. 18 Control experiments included omission of the primary antibody, as well as extensive tests for cross-reactivity of the secondary antibodies. All control experiments resulted in the absence of staining.
Double Immunostaining
To investigate whether antibodies passed the blood brain barrier in immunized rats and bound to hypothalamic hypocretin neurons, the TRIB2-immunized-rat brain sections were also stained with anti-hypocretin antiserum and anti-rat IgG. The sections were incubated with rabbit anti-hypocretin-1 primary antiserum (1:4500, Phoenix Pharmaceuticals Inc.) diluted in 0.4% Triton X-PBS for 48 hours, and followed by 1 hour with a goat Alexa594-labeled anti-rat IgG for the detection of endogenous rat IgG and a goat Alexa488-labeled anti-rabbit IgG for the detection of hypocretin neurons (1:5000) (Molecular Probes, Paisley, UK). The immunoreactive hypocretin and rat IgG signals were visualized under a fluorescence microscope equipped with a digital camera (Olympus BX51; DP70, Tokyo, Japan).
Immunoblotting Analysis
The sera from one intact rat, one KLH-immunized rat, and three TRIB2-immunized rats and the plasma from a 3-week-old hypocretin/ataxin-3 mouse (one female), 12-week-old hypocretin/ataxin-3 mice (two female), over 30-week-old hypocretin/ ataxin-3 mice (three females), a 25-week-old wild-type littermate mouse (one female), and over 30-week-old wild-type littermate mice (two females), were examined for their immunoreactivities against hypothalamic tissue.
Four 8-week-old C57BL/6 mice were purchased from CLEA Japan, Inc. (Tokyo, Japan). The cortex and hypothalamic tissue as a positive control and liver as a negative control from 8-weekold C57BL/6 mice were homogenized with RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) with Protease Inhibitor Cocktail (Roche Diagnostics, Tokyo, Japan). Then, the homogenate was centrifuged and the supernatant was obtained as a soluble fraction. An aliquot of 10 μG of the soluble fraction of tissues was electrophoresed through a denaturing 15% acrylamide gel, and then transferred to a Hybond-P (GE Healthcare Life Science, Pittsburgh, PA). After blocking with skimmed milk, the membranes were incubated with rat sera (1:100) or murine plasma (1:100) for 1 hour at room temperature. After washing three times for 10 minutes with Tris-buffered saline (TBS) (150 mM NaCl, 20 mM Tris, pH 7.4)-0.05% Tween-20 (TBST), the membranes were incubated with a 1:5000 dilution of HRP-labeled Protein-G (Merck, Darmstadt, Germany) in 5% skimmed milk-TBST for 1 hour at room temperature. Subsequently, the proteins were visualized with TMB Membrane Peroxidase Substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD). As a positive control antibody, we used rabbit polyclonal TRIB2 antibody (1:1000, Proteintech Group, Inc., Chicago, IL).
Immunofluorescence Study of Mouse Plasma
To investigate whether antibodies in the plasma obtained from hypocretin/ataxin-3 mice recognize the hypothalamic hypocretin neurons, the murine brain sections were stained with the plasma from hypocretin/ataxin-3 mice and commercially available rabbit anti-hypocretin antiserum. Eight-week-old C57BL/6 mice were perfused transcardially with PBS followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Whole brains were removed, post-fixed, and cryosectioned into 30-µm coronal sections. The hypothalamic brain sections (positive control for hypocretin neurons) (1:4500, Phoenix Pharmaceuticals Inc.) and the plasma from hypocretin/ataxin-3 mice (1:50) diluted in 0.4% Triton X-PBS overnight at room temperature, followed by 1-hour incubation with a goat Alexa594-labeled anti-mouse IgG and a goat Alexa488-labeled anti-rabbit IgG (1:5000) (Molecular Probes, Thermo Fisher Science, Waltham, MA). The resulting hypocretin neurons and mouse IgG signals were visualized under a fluorescence microscope equipped with a digital camera (Nikon ECLIPSE-E1000M Tokyo, Japan).
RESULTS
Immunization With C-Terminal TRIB2 Peptide Induced Anti-TRIB2 Antibodies
With the cutoff value (OD 595 = 1.86), none of the KLHimmunized and intact rats, but all of the TRIB2-immunized rats showed positive reactions against TRIB2 antigen, suggesting that our immunization procedure successfully induced TRIB2 antibody ( Figure 1A ) after 2 weeks from the final immunization (at the age of 21 weeks). Five out of eight CSF samples from TRIB2-immunized rats were positive for anti-TRIB2 antibodies with the CSF cutoff value (OD 595 = .510) ( Figure 1B ) at 21 weeks old. A significant correlation was not found in anti-TRIB2 titers between CSF and sera in any of the measured animals (n = 14, r = 0.325, Figure 1C ), or in TRIB2-immunized animals (n = 6, r = −0.339).
Immunoblot analysis revealed that TRIB2 antibody (15359-1-AP) indicates the existence of TRIB2 proteins from 45 to 55 kDa in the murine cortex and hypothalamus, but not in the liver (Figure 2, arrowhead) . Sera positive for anti-TRIB2 antibodies in TRIB2-immunized rats (Figure 2, panel P1~P3) showed the same size band in the murine hypothalamus. Sera negative for anti-TRIB2 antibodies in KLH-immunized (Figure 2 , panel N1) and intact (Figure 2 , panel N2) rats showed no positive reaction.
Chronic KLH and TRIB2 Immunization Induced the Reduction of Hypocretin mRNA Synthesis and Release
The changes in the rat CSF hypocretin level over time (at 8, 15, 17, 19, and 21 weeks old) are shown as a percentage of the CSF hypocretin level of the age-matched intact rat group CSF. The rates of CSF hypocretin levels were significantly decreased in the KLH group of 19 (mean ± SEM, 82.4 ± 2.0%, p < .005) and 21-week-old rats (76.1 ± 9.4%, p < .05) and the TRIB2 group of 19 (73.3 ± 5.1%, p < .005) and 21-week-old rats (70.3 ± 7.5%, p < .005) compared with the age-matched intact group (19 weeks; 100.0 ± 4.3%, 21 weeks; 100.0 ± 12.3%) ( Figure 3A ). There was no significant difference in CSF hypocretin levels between KLH and TRIB2 groups in 19-or 21-week-old rats ( Figure 3A) . Hypocretin protein contents and mRNA expression in the hypothalamus of these rats were examined to evaluate whether or not transcription, translation, storage, or exocytosis in hypocretin neurons was impaired in 21-week-old immunized rats. There was no significant change in hypothalamic hypocretin contents between immunized and intact groups ( Figure 3B ), although hypocretin mRNA expression was reduced in KLH (mean ± SEM, 1.63 ± 0.14, p < .05) and TRIB2 (1.76 ± 0.14, p < .01)-immunized groups compared with the intact group (2.50 ± 0.33) ( Figure 3C ) using B2m as an internal control. There were no differences in Pmch mRNA levels among the three groups (Intact: 2.09 ± 0.25, KLH: 1.74 ± 0.15, TRIB2: 2.13 ± 0.15) ( Figure 3D ) using B2m as an internal control. These results of mRNA changes were calculated with gene B2m as a housekeeping gene, but the results were the same (significant hypocretin mRNA reduction and no change in Pmch mRNA) when Gapdh or Tbp was used as a housekeeping gene (data not shown).
It is plausible that the decrease in the CSF hypocretin concentration and mRNA might be the result of an increase in sleep bouts; therefore, the effect of 6-hour sleep deprivation was assessed after chronic immunization to investigate the effect of the sleep-wake state. No significant differences in the CSF hypocretin concentration (n = 3, 27.83 ± 5.86) or Figure 2 -Immunoblotting analysis of rat sera. The rat sera positive for anti-TRIB2 antibody in ELISA also reacted with neural TRIB2 protein predicted to be from 45 to 55 kDa in the murine hypothalamus (P1~P3), which was also predicted in the murine cortex and hypothalamus using positive control TRIB2 antibody (15359-1-AP, arrowhead). Sera negative for anti-TRIB2 antibody in KLH-immunized (N1) and intact (N2) rats showed no positive reaction against mouse hypothalamic tissue. hypothalamic hypocretin mRNA (n = 3, 1.69 ± 0.40) in the KLH-immunization with sleep deprivation group were found compared with the KLH-immunization group, suggesting that the decreases in hypocretin mRNA and CSF hypocretin are not dependent on the reduction of vigilance. Moreover, hypocretin mRNA synthesis and the CSF concentration in all immunized and TRIB2-immunized groups were not significantly correlated with anti-TRIB2 antibody titers.
No Change in Hypocretin Cell Number After Immunization
To confirm the cause of hypocretin mRNA reduction, we counted the hypocretin cell number in immunized 21-weekold rats and compared it with that in intact 21-week-old rats. No change was found in the number of hypocretin neurons of immunized rats (mean ± SEM, KLH: 2208 ± 179, TRIB2: 2012 ± 167) compared with intact rats (2101 ± 199), suggesting that the transcriptional activity for hypocretin mRNA of hypocretin neurons was impaired after immunization.
Positive Signal With Rat IgG in TRIB2-Immunized Rats of Hypocretin Neurons
The IgG-binding signal against hypocretin neurons was found in the brain section from 21-week-old TRIB2-immunized rats (Figure 4) , suggesting that peripheral circulating antibodies reached the central nervous system, but exhibited no cytotoxicity against hypocretin neurons.
The Ablation of Hypocretin Neurons Increased the Titer of Anti-TRIB2 Antibodies
To confirm whether anti-TRIB2 antibody is induced as a result of the hypocretin cell destruction and release of its contents in the peripheral tissues, we examined the reactivity of the plasma against TRIB2 peptide obtained from hypocretin/ataxin-3 mice using ELISA. With the cutoff value using the plasma obtained from young mice before hypocretin neuron ablation (3-and 4-week-old hypocretin/ataxin-3 mice; seven females and five males) (OD 595 = 0.207), two out of twelve 12~26-week-old mice and twelve out of eighteen 28~38-week-old mice were positive for anti-TRIB2 antibodies ( Figure 5A ).
The plasma positive for anti-TRIB2 antibody on ELISA from a 31-week-old female hypocretin/ataxin-3 mouse reacted with the protein from 45 to 55 kDa in the murine hypothalamus ( Figure 5B, arrowhead) , which was predicted by positive control TRIB2 antibody (Figure 2 ). The plasma negative for anti-TRIB2 antibody on ELISA from a 25-week-old female hypocretin/ataxin-3 mouse, a 3-week-old female hypocretin/ ataxin-3 mouse, and an over 30-week-old female wild-type littermate showed no reaction against the hypothalamus ( Figure 5B ). The plasma from a 32-week-old female wild-type mouse stained three bands, which were not TRIB2, from 50 to 65 kDa in the liver, indicating that autoantibodies targeting proteins other than hypocretin were created in hypocretin/ ataxin3 mice. The signals stained by the plasma from 31-week-old female hypocretin/ataxin-3 mice were clearly the same as the signal stained by rabbit anti-hypocretin-1 antiserum in the hypothalamic region ( Figure 5C ). No colocalizaton with the DAPIlabeled nucleus was found in the plasma from 31-week-old female hypocretin/ataxin-3 mice. In contrast, no signal with hypothalamic hypocretin neurons was found in the plasma from one 3-week-old female hypocretin/ataxin-3 mouse, one 25-week-old female hypocretin/ataxin-3 mouse, and two over 30-week-old female wild-type littermate mice ( Figure 5D , Supplementary Figure S1 ). The plasma from 32-week-old female wild-type littermates stained blood vessels ( Figure 5D ).
DISCUSSION
Archelos and Hartung have outlined five criteria to establish a causal link between an autoantibody and a neurological disease. 19 Applied to narcolepsy, they would be:
1. The presence of the autoantibody in the sera and ideally CSF of individuals with narcolepsy but not controls. The first criterion is verified by Cvetkovic-Lopes's report.
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Regarding the second point about the existence of immunoglobulin around hypocretin neurons in narcolepy at onset, this is difficult to clarify, because narcolepsy is not a fatal disease. However, at least in the postmortem histological investigation, there was no immune reaction around hypocretin neurons. 20 Concerning the third point about plasma exchange, there was a clinical report by Chen et al. 21 The forth point about the passive transfer of TRIB2 antibody was reported by Katzav et al. 15 The last point regarding that narcolepsy induction with purified antigen has yet to be verified. Therefore, we attempted to verify the last point in this study by purified-TRIB2 immunization.
We expected TRIB2 immunization to trigger hypothalamic hypocretin neuron loss and have a causal relationship with the pathophysiology of narcolepsy; however, anti-TRIB2 antibody did not induce narcolepsy in our rat experiments, and our data did not support the hypothesis. Instead, we found that anti-TRIB2 antibody increased as a result of the loss of hypothalamic hypocretin neurons with the advance of hypocretin neuron ablation in hypocretin/ataxin-3 mice. The increased titer of anti-TRIB2 antibody is at least partly a consequence of hypocretin neural loss, in addition to playing a possible role as a precipitating factor. In terms of the elevated anti-TRIB2 antibody titer, this result suggests that once hypothalamic hypocretin neurons are destroyed, it could work as an exacerbating factor facilitating an autoimmune process against hypocretin neurons.
Decreases in the hypocretin content and mRNA levels in chronic TRIB2 and KLH immunized rat suggest that the mRNA synthesis of hypocretin in hypocretin neurons and hypocretin release were suppressed by the chronic immunological challenge. There was no significant correlation between TRIB2 antibody titers and hypocretin mRNA or TRIB2 antibody titers and hypocretin release.
Then, how was the transcriptional activity for mRNA of hypocretin neurons impaired after immunization? We hypothesized that the Interferon (IFN)-alpha system is a candidate regulator of hypocretin activity. IFN-alpha, a cytokine involved in defense against viral infections, modulates the expression of preprohypocretin in vitro, and this effect is likely to be mediated through its binding to an IFN-stimulated regulatory element in the 5′-upstream region of the preprohypocretin gene. 22 Furthermore, IFN-gamma has been reported to increase in the sera of narcoleptic patients. 23 Therefore, the IFN system might be one of the candidates to regulate hypocretin transcription. We considered that the general activation of the immune system could modulate the hypocretin neuron activity, as reported by Grossberg et al. 24 They showed that lipopolysaccharide (LPS) injection suppressed hypocretin signaling and induced inactivity.
The transmission of TRIB2 autoantibody across the blood brain barrier was supported by the findings of an increased titer of CSF anti-TRIB2 antibody and the existence of rat IgG binding in hypocretin neurons from immunized rat hypothalamic tissue. The number of hypocretin cells was, however, not changed in any of the immunized rat groups, suggesting no specific cytotoxicity in rats by the current TRIB2 autoantibodies induced by immunization of TRIB2 C-terminal antigens. These results indicate the general activation of the immune system, not being restricted to an immune response to a specific antigen, affecting the function of hypocretin neurons.
LPS injection induced non-specific immune challenge and sickness-associated behavior, such as low-level locomotor activities and inhibition of the response to emotional stimuli. LPS injection suppressed hypocretin signaling and induced inactivity. 24 The hypocretin neuron is one critical regulator of the arousal system. 25 Hypocretin neurons are also related to reward-oriented stimuli such as reward/drug-seeking 26 and sex-related behavior, 27 which should be suppressed during sickness behavior. Our results showing that the function of hypocretin neurons (synthesis and release) was suppressed even in KLH-immunized rats are in line with the physiological role of hypocretin against immune challenge.
We need to consider the specificity of the circumventricular organs 28, 29 around the hypothalamus, where blood vessels typically do not function as a barrier. These areas are largely delimited from the hypothalamus by tanycytes. Moreover, the integrity of the blood brain barrier has been reported to be dis- rupted by inflammatory cytokines, such as TNF-α. 30, 31 In our experiment using a chronic TRIB2-immunization protocol, cytokines or other factors could induce blood brain barrier dysfunction, so that peripheral autoantibodies could go through the barrier and affect the neuronal function.
In chronic TRIB2 or KLH immunized rats, showing an increased titer of CSF anti-TRIB2 antibody and a positive IgG binding/signal in hypocretin neurons, there were no decreases of the hypocretin cell number or hypocretin contents. These results indicate that anti-TRIB2 antibody induced in our experiments was not cytotoxic to hypocretin cells. In the TRIB2-immunized rat brain, some hypocretin cells were also positive for rat IgG without apparent morphological changes, suggesting that rat IgG might not affect hypocretin neural survival.
In our experiment, we identified decreases of hypocretin release and mRNA synthesis. There are a number of reports that discuss autoantibodies' regulation of neuronal activities other than cytotoxicity. For instance, anti-thyroid hormone-stimulating hormone (TSH) receptor in Hashimoto thyroiditis blocks the binding of TSH, resulting in hypothyroidism with the gradual depletion of stored T 4 and T 3 thyroid hormones, 32 and autoantibody against muscarinic cholinergic receptor in chronic fatigue syndrome may act as a receptor agonist or antagonist 33 without the impairment of acetylcholinesterase activity. 34, 35 Taken together, some IgG found in immunized rat lateral hypothalamic tissue in our experiment may modulate hypocretin transcriptional activity and exocytosis without cytotoxicity.
Neurons other than hypocretin-containing cells are relatively preserved in narcolepsy patients, 36, 37 while TRIB2 is widely expressed throughout the brain, 38 so the cytotoxic effect of anti-TRIB2 antibodies could not be specific for hypocretin neurons. It is also important to verify whether the effect of the general immunization is specific to hypocretin neurons or may also target other hypothalamic neurons, such as MCH and histaminergic neurons. We reported that there was no significant difference between the effect of saline and LPS injections on Hdc and Hnmt expressions in the hypothalamus of 12-weekold wild-type male mice. 39 However, the suppression of Aoc1 expression, which is a histamine metabolism enzyme, was noted after LPS injection. 40 There was no significant difference in Pmch expression between the LPS and saline treatments in our study, 39 which is consistent with the findings of a previous study. 41 Therefore, the effect of general immunization depends on the type of neuron and mRNA. The hypocretin neuron is very sensitive to outside intervention. We observed a hypocretin (both peptide and mRNA) decrease on saline microinjection in the lateral hypothalamus. Taken together, we suggest that the effect of non-specific immune enhancement is particularly marked in the case of hypocretin.
In this study, we found an increased titer of anti-TRIB2 antibodies after the advanced hypocretin neuron ablation in hypocretin/ataxin-3 mice, suggesting that anti-TRIB2 antibodies may be a consequence rather than the cause of hypocretin cell destruction. Released intracellular TRIB2 protein followed by the degeneration of hypocretin neurons might lead to the formation of autoantibodies. Another possible explanation is that anti-TRIB2 antibodies might be induced as naturally occurring antibodies without injuring hypocretin neurons. Since anti-TRIB2 antibodies were more prevalent in HLA-DQB1*0602-positive narcolepsy with cataplexy patients compared with narcolepsy without cataplexy patients negative for HLA-DQB1*0602, 13 the difference in the antigen presentation process by HLA might be a key factor to produce such a naturally occurring antibody which cross-reacts with TRIB2 antigens.
Our results suggest the possibility that peripheral immune challenge affects the changes in the status of hypocretin neurons. Significant increases in interleukin-6 (IL-6), a pro-inflammatory cytokine, were noted in the blood of narcolepsy patients 42, 43 and in the rat hypothalamus with the acute peripheral administration of a low dose of 44 and re-exposure to LPS. 45 Signal transducer and activator of transcription 3 (STAT3) colocalizes with hypothalamic hypocretin neurons. 46 STAT3 is known to be activated through tyrosine phosphorylation in response to cell-surface cytokine receptors, such as the IL-6 signal transducer (also known as gp130), 47 suggesting the direct connection of the peripheral immunological status with the function of hypocretin neurons. Since proprotein convertase subtilisin/ kexin type 1 (PCSK1), a candidate cleavage enzyme for hypocretin-1 and -2, is regulated by gp130-related cytokines, 48 the disturbance of hypocretin release being dependent on an unusual PCSK1 function is speculated under chronic immunological stress. An investigation of the gene expression pattern and phosphorylation status using laser microdissected-hypocretin neurons is needed after immunization in a future study.
The serum of a narcolepsy patient positive for TRIB2 antibody stained over 86% of hypocretin neurons and absorption with TRIB2-peptide resulted in a marked decrease of staining to less than 8% of hypocretin neurons 11 ; therefore, almost all hypocretin neurons exhibit TRIB2 expression. In our experiment, murine hypothalamic sections were specifically double-stained by plasma from a 31-week-old hypocretin/ataxin-3 mouse and rabbit anti-hypocretin-1 antiserum. Together with TRIB2 expression in almost all hypocretin neurons and plasma specificity, our findings strongly suggest that the ablation of hypocretin neurons induces autoantibodies against TRIB2, hypocretin itself, or specific factors expressed in hypocretin neurons. An about 140-kDa band reacting with the plasma from a hypocretin/ataxin-3 mouse might be one such specific factor, and so the identification of such a band could be useful for estimating the degree of hypocretin neuronal loss.
Contrary to our initial expectations, the alteration of hypocretin activities was found in immunized rats regardless of TRIB2 antigenicity. Since the general immunological change affects hypocretin neurons, direct immunological evidence of hypocretin neurons is necessary by demonstraing colocalization with cytokine receptors or major histocompatibility complex class I proteins 49 in hypothalamic hypocretin neurons.
